Drug
Becotatug vedotin clinical trials
Also written MRG003.
Keep track of what changes. Save the becotatug vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2026 (41)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 41 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 41
Lepu Biopharma Co., Ltd. (10) · Sun Yat-sen University (8) · Fudan University (5) · Tianjin Medical University Cancer Institute and Hospital (3) · West China Hospital (2) · Jiyan Liu (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Jiangmen Central Hospital (1)
Often tested with
Tested in the same studies.
Pucotenlimab (17) · Tislelizumab (2) · Immune Checkpoint Inhibitors (2) · Pembrolizumab (1) · Ado-Trastuzumab Emtansine (1) · Trastuzumab deruxtecan (1) · Datopotamab deruxtecan (1) · Sacituzumab govitecan (1)
Studies
Open first, then newest update. How each study uses becotatug vedotin is read from its arms, and is right about nine times in ten.
Testing it · 51
- Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerEnrolling by invitationPhase 2Jiangmen Central HospitalNCT07890311Written as MRG003 (Becotatug Vedotin)
- Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard TherapyRecruitingNot applicableNingbo Medical Center Lihuili HospitalNCT07892573Written as Becotatug Vedotin
- Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later SettingRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT07892833Written as Becotatug vedotin (MRG003)
- Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07882940Written as Becotatug Vedotin (MRG003)+pucotenlimab+platinum
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT07884188Written as Becotatug Vedotin (MRG003)
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingPhase 2Fujian Cancer HospitalNCT07331428Written as MRG003
- Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLCRecruitingNot applicableShanghai Pulmonary Hospital, Shanghai, ChinaNCT07874581Written as MRG003 (Becotatug Vedotin)
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingPhase 2Huashan HospitalNCT07844551Written as Becotatug Vedotin (MRG003)
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Becotatug vedotin (MRG003)
- A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2West China HospitalNCT07381075Written as Becotatug Vedotin
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT05751512Written as MRG003
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT05688605Written as MRG003+HX008
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT06976190Written as MRG003 + Pucotenlimab
- Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingPhase 2Hongmeng YuNCT07781358Written as Becotatug Vedotin
- Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07766889Written as Becotatug Vedotin (MRG003)
- Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07767266Written as Pucotenlimab plus Becotatug Vedotin
- MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Dongguan People's HospitalNCT07677475Written as MRG003 (Becotatug vedotin) and Toripalimab
- EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingPhase 2Jiyan LiuNCT07518979Written as Becotatug Vedotin
- A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic CarcinomaRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07522879Written as Becotatug Vedotin
- Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingPhase 2Tianjin Medical University Second HospitalNCT07712029Written as Becotatug Vedotin
See all 51 studies that test becotatug vedotin →
Given in every arm · 4 — becotatug vedotin is usual care beside what is tested
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07874321Written as Becotatug Vedotin (MRG003)
- Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2West China Second University HospitalNCT07692334Written as Becotatug Vedotin (MRG003)
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT06959108Written as MRG003
- The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort StudyRecruitingPhase 2Ji DongmeiNCT07464366Written as MRG 003
Codes
What other systems call becotatug vedotin · ClinicalTrials.gg INT018246
- UNII (FDA) VHA6L8H5FMBECOTATUG VEDOTINOne source FDA
- NCI Thesaurus C180585Becotatug VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VHA6L8H5FM | BECOTATUG VEDOTIN | One source FDA |
| NCI Thesaurus | C180585 | Becotatug Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.